Ausgabe 5/2020
Inhalt (13 Artikel)
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials
Sarah Cargnin, Jae Il Shin, Armando A. Genazzani, Alessia Nottegar, Salvatore Terrazzino
A preliminary assessment of oral monepantel’s tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors
Anna Mislang, Richard Mollard, Gonzalo Tapia Rico, W. Douglas Fairlie, Erinna F. Lee, Tiffany J. Harris, Roger Aston, Michael P. Brown
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial
Hong Xiang, Lucy Liu, Yuying Gao, Ago Ahene, Monica Macal, Amy W. Hsu, Lyndah Dreiling, Helen Collins
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, Genichi Kusakawa, Takumi Sakai, Yugo Uchida, Mikihiro Takamoto, Saki Kimoto, Ichinosuke Hyodo
Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia
Chandra Prakash, Bin Fan, Alice Ke, Kha Le, Hua Yang
In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine
Anand Joshi, Brian F. Kiesel, Nupur Chaphekar, Reyna Jones, Jianxia Guo, Charles A. Kunos, Sarah Taylor, Edward Chu, Raman Venkataramanan, Jan H. Beumer
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Yoriko Yamashita-Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura, Naoki Harada, Yasushi Yoshimura
Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system
Qianqian Fan, Jie Ma, Bo Zhang, Qiuyue Li, Fang Liu, Bin Zhao
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1
Jinghua Huang, Changxiu Lin, Hai Dong, Zhengri Piao, Chunhua Jin, Hengmin Han, Dongchun Jin
Efficacy and safety of oral magnesium supplementation in reducing febrile neutropenia episodes in children with solid tumors treated with cisplatin-based chemotherapy: randomized clinical trial
Osvaldo D. Castelán-Martínez, Miguel A. Palomo-Colli, Victoria E. Barrios-López, Karla M. Silva-Jivaja, Luis E. Juárez-Villegas, Gilberto Castañeda-Hernández, Martha A. Sánchez-Rodríguez
Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion
Heitor Pinhata Cecilio, Vitor Bonetti Valente, Karla Marcila Pereira, Giseli Mitsuy Kayahara, Cristiane Furuse, Éder Ricardo Biasoli, Glauco Issamu Miyahara, Sandra Helena Penha Oliveira, Daniel Galera Bernabé
Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples
Chadi Abbara, Guillaume Drevin, Séverine Férec, Sarah Ghamrawi, Simon Souchet, Jean-Baptiste Robin, Aline Schmidt, Mathilde Hunault-Berger, Philippe Guardiola, Marie Briet
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses
Yoshinao Ozaki, Hirotaka Imamaki, Aki Ikeda, Mitsuaki Oura, Shunsaku Nakagawa, Taro Funakoshi, Shigeki Kataoka, Yoshitaka Nishikawa, Takahiro Horimatsu, Atsushi Yonezawa, Takeshi Matsubara, Motoko Yanagita, Manabu Muto, Norihiko Watanabe